Literature DB >> 22094875

ATM-mediated DNA damage signals mediate immune escape through integrin-αvβ3-dependent mechanisms.

Masahisa Jinushi1, Shigeki Chiba, Muhammad Baghdadi, Ichiro Kinoshita, Hirotoshi Dosaka-Akita, Koyu Ito, Hironori Yoshiyama, Hideo Yagita, Toshimitsu Uede, Akinori Takaoka.   

Abstract

Although the tumor microenvironment plays a critical role in tumor progression and metastasis, the relationship between chemotherapy resistance and modulation of the tumor microenvironment remains unclear. Here, we report a novel mechanism showing how constitutive DNA damage signals in therapy-resistant tumor cells suppress antitumor immunity in an integrin-αvβ3-dependent manner. Integrin-αvβ3 was upregulated on various therapy-resistant tumor cells through chronic activation of ATM/Chk2-and NFκB-mediated pathways. Inhibiting tumor-specific expression of integrin-αvβ3 improved therapeutic responses to anticancer drugs by stimulating endogenous host immune systems. Mechanistic investigations revealed that tumor-specific integrin-αvβ3 expression targeted dendritic cells, facilitating their ability to phagocytose viable therapy-resistant tumor cells and thereby impaired their ability to cross-prime antigen-specific T lymphocytes. Together, our results clarify the detrimental effects of constitutive DNA damage signals to chemosensitivity and antitumor immunity. Furthermore, these findings suggest that integrin-αvβ3 targeting may benefit patients' refractory to current anticancer regimens by defeating DNA damage signaling-induced immune escape. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22094875     DOI: 10.1158/0008-5472.CAN-11-2028

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Mps1 is associated with the BRAFV600E mutation but does not rely on the classic RAS/RAF/MEK/ERK signaling pathway in thyroid carcinoma.

Authors:  Yike Li; Yanyan Zhang; Shuaishuai Xiao; Pengzhou Kong; Caixia Cheng; Ruyi Shi; Fang Wang; Ling Zhang; Juan Wang; Zhiwu Jia; Shuai Wu; Yun Liu; Jiansheng Guo; Xiaolong Cheng; Yongping Cui; Jing Liu
Journal:  Oncol Lett       Date:  2018-04-24       Impact factor: 2.967

Review 2.  Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance.

Authors:  Laetitia Seguin; Jay S Desgrosellier; Sara M Weis; David A Cheresh
Journal:  Trends Cell Biol       Date:  2015-01-05       Impact factor: 20.808

3.  An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.

Authors:  Laetitia Seguin; Shumei Kato; Aleksandra Franovic; M Fernanda Camargo; Jacqueline Lesperance; Kathryn C Elliott; Mayra Yebra; Ainhoa Mielgo; Andrew M Lowy; Hatim Husain; Tina Cascone; Lixia Diao; Jing Wang; Ignacio I Wistuba; John V Heymach; Scott M Lippman; Jay S Desgrosellier; Sudarshan Anand; Sara M Weis; David A Cheresh
Journal:  Nat Cell Biol       Date:  2014-04-20       Impact factor: 28.824

Review 4.  Autophagy proteins regulate cell engulfment mechanisms that participate in cancer.

Authors:  Sung Eun Kim; Michael Overholtzer
Journal:  Semin Cancer Biol       Date:  2013-05-30       Impact factor: 15.707

5.  An RGDKGE-Containing Cryptic Collagen Fragment Regulates Phosphorylation of Large Tumor Suppressor Kinase-1 and Controls Ovarian Tumor Growth by a Yes-Associated Protein-Dependent Mechanism.

Authors:  XiangHua Han; Jennifer M Caron; Christine W Lary; Pradeep Sathyanarayana; Calvin Vary; Peter C Brooks
Journal:  Am J Pathol       Date:  2020-12-08       Impact factor: 4.307

6.  Chronic activation of DNA damage signals causes tumor immune evasion in the chemoresistant niche.

Authors:  Masahisa Jinushi
Journal:  Oncoimmunology       Date:  2012-05-01       Impact factor: 8.110

Review 7.  DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy.

Authors:  Ruixue Huang; Ping-Kun Zhou
Journal:  Signal Transduct Target Ther       Date:  2021-07-09

Review 8.  β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer.

Authors:  Anne-Florence Blandin; Guillaume Renner; Maxime Lehmann; Isabelle Lelong-Rebel; Sophie Martin; Monique Dontenwill
Journal:  Front Pharmacol       Date:  2015-11-24       Impact factor: 5.810

9.  Loss of BAP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development.

Authors:  Carlos R Figueiredo; Helen Kalirai; Joseph J Sacco; Ricardo A Azevedo; Andrew Duckworth; Joseph R Slupsky; Judy M Coulson; Sarah E Coupland
Journal:  J Pathol       Date:  2020-04       Impact factor: 7.996

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.